Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humanized CAR19T2 T Cell in Children With Refractory/Relapsed B-cell Leukemia/Lymphoma
NCT05613348Phase 2Withdrawn
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CAR19T2 in B cell acute lymphoblastic leukemia (B-ALL), B cell lymphoma, sponsored by Southern Medical University Zhujiang Hospital. Planned start Dec 2022; status: withdrawn.
02
Drugs
CAR19T2
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT05613348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613348.